A new ruling by the US Food and Drug Administration has mandated that training available through its Opioid Analgesic Risk Evaluation and Management Strategy (REMS) be available to pharmacists.
The now-approved final version of REMS has been expanded to include immediate-release opioid analgesics intended for use in outpatient settings, as well as extended-release and long-acting opioids which have been subject to a REMS since 2012.
The new REMS requires that education for pharmacists, nurses & prescribers cover broader details of appropriate pain management including alternatives to opioids.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Sep 18
